Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,138 total articles
Legacy Housing (LEGH) trades at roughly $19.20 with a market cap near $457M, a P/E of ~11 and P/B under 1. The company generates meaningful free cash flow but faces a growth reset and execution risk. This trade idea buys the mismatch between valuation and near-term cash earnings, with a clearly defined stop and a target that assumes modest re-ratin…
Bumble’s recent cash generation plus an underappreciated tax shield create an outsized free cash flow picture even after conservative adjustments. At the current price, a disciplined long toward $6.00 over the next 45 trading days offers a risk-reward that merits a tactical allocation, provided management sustains margin recovery and execution on A…
Gold.com, Inc. (GOLD) has pulled back sharply with gold price volatility and risk-off flows. The stock now trades at an attractive free-cash-flow-backed valuation, has a modest dividend, and shows oversold technicals. This trade idea lays out an entry at $44.00, a hard stop at $38.00, and a primary target of $62.00 for the recovery trade over the n…
Marvell (MRVL) has been one of the year's strongest AI-levered performers, reporting double-digit growth and routing into custom ASICs, optics, and networking where hyperscalers are spending. The stock trades at a premium but still offers upside relative to the current share price if AI infrastructure spending continues. This trade idea lays out an…
S&P Global is uniquely positioned to monetize the AI data and benchmark arms race. Solid cash flow, recurring margins and exposure across indices, ratings and data services justify a mid-term long trade. Entry $425.00, target $520.00, stop $395.00 — horizon: mid term (45 trading days).
Boundless Bio is a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) cancers. With IND acceptance for BBI-940, $107.6M in cash runway through mid-2028, and a market cap of roughly $26M, the stock offers an asymmetric risk/reward for traders willing to stomach biotech binary events. This trade idea outlines a long trade with en…
Geely (GELYF) shows constructive technicals and a sharp decline in short interest that support a tactical long. Enter at $2.34, stop at $2.05, primary target $2.70 over the next 45 trading days.
TripAdvisor has been beaten down to a sub-$10 stock after a string of near-term misses, but Starboard Value's 9% stake and push for a strategic review materially raise the odds of a re-rating. At an enterprise value of ~$1.24B, EV/EBITDA of 5.8x and free cash flow of $163M, the risk/reward favors a long swing trade while the activist process unfold…
Toast is a restaurant-focused SaaS and payments platform trading near $27.40. With guidance implying roughly $2.3B in ARR for 2026, $608M in free cash flow, and a healthy cash position, the bull case is simple: sustained net new locations and EBITDA expansion should drive multiple expansion from current EV/ARR levels. This trade idea recommends a l…
FLEX LNG's limited spot exposure and heavy dividend make it a tactical long as geopolitical friction around Iran lifts freight rates. The company is well-capitalized with $448M in cash and a $1.71B market cap, but technicals and rising shorts increase short-term risk. This trade targets $36 with a $28 stop over a mid-term (45 trading day) window.
Cboe Global Markets owns franchise assets tied directly to market activity and volatility. With record derivatives revenue traction, strong free cash flow and a modest payout, CBOE is a pragmatic hedge for portfolios anticipating higher volatility. We outline a mid-term trade with entry, stop and target, plus the key catalysts and risks to watch.
CACI is arguing it is misclassified as an IT services name. That dispute matters because a reclassification toward defense/aerospace peers could meaningfully change multiples. The company has solid fundamentals, recurring government revenue, recent M&A and contract wins, and technicals that support a mid-term long trade. Entry: $613.03. Stop: $585.…
Rio Tinto looks like a high-quality cyclical miner trading below near-term trendlines after the collapse of merger talks with Glencore. Fundamentals are intact: $108.8B market cap, a 4.2% yield, and exposure to rising copper demand plus new lithium investments. We upgrade to a buy and propose a mid-term swing trade with defined entry, target and st…
VALE S.A. looks priced for disappointment today despite a $67B market cap, a sub-2x price-to-book ratio, and an eye-catching dividend yield near 8.7%. Combine cyclical tailwinds for iron ore with durable nickel exposure for batteries, and the risk-reward favors a long position over the next 180 trading days. This trade plan includes a clear entry, …
Galiano Gold (GAU) shows technical oversold readings, falling short interest and steady volume after a soft stretch. The trade: enter near $2.29, stop $1.90, target $3.60, mid-term horizon (45 trading days). Thesis balances recovery signals against ongoing operational and macro risks.
Signet Jewelers is reporting resilient top-line and an exceptional free cash flow profile that, combined with a strategic pivot into lab-grown diamonds, makes the stock an appealing long. Valuation metrics (EV/EBITDA ~4.5, P/S ~0.47) and a FCF yield above 16% provide a margin of safety. The trade plan targets a retest of prior highs while protectin…
Verastem is trading at $5.82 with tangible clinical readouts and regulatory milestones looming into the first half of 2026. The balance sheet and enterprise value leave room for partner-led upside; we maintain Buy with a long-term trade plan to capture data-driven revaluation while limiting downside with a tight stop.
Copa Holdings (CPA) looks like a structurally profitable regional airline that has been punished in the short term. With a market cap near $4.56B, a P/E around 6.8, and a dividend yield close to 5.93%, the stock offers asymmetric upside if traffic and margins remain healthy. This trade idea lays out a clear entry at $111.00, a stop at $95.00 and a …
Brookfield Asset Management is seeing assets under management climb alongside a steady free cash flow profile and low leverage. The setup offers a mid-term opportunity to capture mean reversion toward prior valuation levels, with entry at $43.50, a stop at $40.00 and a $52.00 target over the next 45 trading days.
FactSet (FDS) is being punished in the market as investors extrapolate AI-driven disintermediation across financial services. That narrative discounts FactSet's subscription durability, 27.7% ROE, $647M in free cash flow and a sub-13x P/E. We recommend a tactical long for a mid-term rebound: enter at $207.49, stop $190.00, target $260.00 (45 tradin…
Alibaba reported a mixed quarter on 03/19/2026: revenue growth slowed to +2% while adjusted EBITA plunged 57%, but cloud intelligence revenue and AI product traction remain strong. The stock is trading oversold with a 14-day RSI ~26 and a market cap near $302B. I think this is a worthwhile long trade on weakness with defined entry, stop and a 180-t…
A pullback in private credit is reducing the ability of smaller chip startups and captive AI silicon projects to scale. That dynamic benefits incumbents that combine design scale, foundry relationships, and clean balance sheets. Advanced Micro Devices (AMD) checks those boxes: $6.7B free cash flow, near-zero leverage, and a market cap of roughly $3…
Abeona (ABEO) is a small-cap gene-therapy developer that now has an FDA-approved, autologous cell-based therapy - ZEVASKYN - for RDEB. With approval in hand and early payer coverage, the stock offers a high-risk, high-reward trade: entry at $4.53, stop at $3.70, target $8.00 over a 180 trading-day horizon.
Ichor reported an earnings beat and issued optimistic 2026 quarterly guidance, signaling margin recovery and sequential revenue growth. With a $1.68B market cap, improving short interest dynamics and low leverage, the stock has room to run. This trade idea outlines an actionable mid-term long with entry, stop and target levels and balanced risk con…
L'Oreal's recent share buyback, steady 2025 sales of €44.05 billion and a technically oversold ADR (RSI ~31) create a compelling setup for long-term investors. I upgrade the name to attractive for a long-term trade with a clear entry at $79.90, a stop at $70.00 and a target of $95.00 over the next 180 trading days.
